Divi’s Laboratories, a leading active pharmaceutical ingredients (API) manufacturer, reported a 64.52% rise in its consolidated profit after tax (PAT) for the quarter ending December 2024, reaching ₹589 crore, up from ₹358 crore in the same period last year, according to the company’s exchange filing.
Revenue from operations for Q3 FY25 surged by 25% to ₹2,319 crore, compared to ₹1,855 crore in Q3 FY24.
EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortisation) also saw a significant increase of 52%, reaching ₹743 crore for the quarter, up from ₹489 crore in the previous year. The EBITDA margin improved to 32%, compared to 26.4% in Q3 FY24.
As of 1:32 PM, Divi’s Laboratories shares were trading 3.85% higher at ₹5,834.85 on the National Stock Exchange (NSE).
In its regulatory filing, the company mentioned a forex gain of ₹10 crore for the current quarter, compared to ₹18 crore in the same quarter of the previous year.
Performance for 9M FY25
For the nine months ending December 31, 2024, Divi’s Laboratories reported a 43.97% increase in net profit, totaling ₹1,529 crore, compared to ₹1,062 crore in the same period last year.
The company reported consolidated total income of ₹7,041 crore for 9M FY25, up from ₹5,804 crore in the same period the previous year. Profit Before Tax (PBT) for the nine months stood at ₹2,052 crore, compared to ₹1,450 crore for the same period in FY24.